Energy · Metabolic · Longevity Rx · Prescription required

MOTS-c.

Mitochondrial Open Reading Frame

A mitochondrial-derived peptide that improves insulin sensitivity, metabolic flexibility, and exercise capacity. Acts where ageing actually starts — the mitochondrion.

MW 2174.5 Molecular weightThe mass of one molecule of MOTS-c in g/mol. Larger than most signaling peptides — fully characterized.
Sequence 16 aa Peptide chain length16 amino acids — encoded within the mitochondrial 12S rRNA gene. A novel class: mitochondrially-derived peptides (MDPs).
Route Sub-Q How you take itSubcutaneous: under the skin. Same technique as a GLP-1 or insulin pen.
Cycle 10 wk Cycle lengthTypical 8–12 week cycle at 3× weekly, then off-cycle. The metabolic adaptations accrue over weeks.
Discovered 2015 First isolatedMOTS-c was first reported by Lee et al in 2015 — the founding member of the mitochondrially-derived peptide class.
Begin your protocol Free assessment · No card · Rx required
MOTS-c Metabolic
MW 2174.5 Length 16 aa Route Sub-Q Cycle 10 wk
Begin →
01 The case

Where ageing actually starts.

MOTS-c is a peptide encoded inside the mitochondrion — not in the nucleus. The discovery (Lee et al, 2015) established a new class: mitochondrially-derived peptides. The implication is large: the mitochondrion isn't just an energy factory, it's a signaling organ.

What MOTS-c does is improve metabolic flexibility. It activates AMPK, sensitizes cells to insulin, and improves the way mitochondria respond to energy demand. In animal models, exercise capacity rises and metabolic syndrome features improve.

It is exploratory — newer than most peptides on this site, with less human evidence. But the mechanism is rare and clean: it targets the cellular structure most age-related decline tracks back to.

02 Mechanism

Where it acts.

Six effects converge on one organelle — the mitochondrion. The metabolic axis runs through here.

MOTS-c C₁₀₃H₁₅₅N₂₇O₂₅S
⌬ AMPK activation Master metabolic switch — energy-sensing kinase
⊖ Insulin sensitization Improves cellular response to insulin
∿ Glucose homeostasis Better disposal during high-load periods
◐ Mitochondrial signaling Novel signaling axis from the organelle
↗ Exercise mimetic Mimics endurance-training adaptations
⌒ Metabolic flexibility Switches cleanly between substrates
03 Evidence

A new peptide class.

MOTS-c is younger than most peptides we offer. The mechanism is mostly preclinical; human studies are emerging.

2015

year MOTS-c was first reported (Lee et al)

Cell Metabolism · 2015
AMPK

the master metabolic switch — established target

Mechanism review
Novel

first member of the mitochondrially-derived peptide class

Class founder
16 aa

small bioactive fragment encoded in mitochondrial DNA

Peptide chemistry
04 Who it's for

Built for the metabolic axis.

Most often prescribed for metabolic concerns — insulin sensitivity, fatigue, exercise capacity, and as an exploratory longevity tool.

⊖

Insulin sensitivity

Cellular response improvement over weeks.

⌒

Energy / fatigue

Mitochondrial output drives subjective energy.

↗

Exercise capacity

Endurance and recovery improvement.

⚛

Metabolic syndrome

Adjunctive support for the cluster.

◐

Healthy aging

Mitochondrial maintenance is a longevity foundation.

∿

Glucose regulation

Disposal during high-load periods.

05 Protocol

A sample protocol.

MOTS-c is dosed three times weekly during a multi-week cycle. Your physician sets the cadence.

Sample parameters

Illustrative
Route
Subcutaneous injection
Dose
5–10 mg
Frequency
3× weekly (M / W / F)
Cycle
10 weeks on · 4 weeks off
Storage
Refrigerated, light-protected

Cycled, not continuous. MOTS-c is run in 10-week cycles followed by an off period. Compounded fresh by a 503A pharmacy to USP 797 sterile standards.

The cadence

Your week 7 days · 3× weekly
MAM
T
WAM
T
FAM
S
S
Your cycle 8 wk · 7 on, 1 off (illustrative)
1on
2on
3on
4on
5on
6on
7on
8off
~3 min per dose Site rotates: abdomen · thigh
06 What arrives

In the box.

Compounded fresh, cold-chain shipped overnight from a U.S.-based 503A pharmacy. Everything you need to start the same week.

⚲
Compounded vials

Multi-dose vial · USP 797 sterile · beyond-use date printed.

⊕
Injection supplies

Insulin syringes, alcohol pads, bacteriostatic water for reconstitution.

❄
Cold-pack shipping

Insulated overnight delivery with ice pack. Tracked door to door.

📖
Step-by-step guide

Reconstitution, dosing math, injection technique, sharps disposal.

07 Often paired with

Stacks that work.

MOTS-c pairs naturally with anything that reinforces mitochondrial health or the broader longevity stack.

NAD+

NAD+ provides the cofactor; MOTS-c provides the signal. Both target the same organelle.

MitochondrialFrom $200/mo →
Sermorelin

GH axis support layered with mitochondrial signaling — two large age-related axes covered.

LongevityFrom $195/mo →
Glutathione

Redox baseline for high mitochondrial activity.

FoundationPricing soon →
08 Safety

Side effects, fine print, responsibility.

MOTS-c is exploratory. Human safety data is limited; here's what the published literature reports.

✓

What to expect

  • 01Mild injection-site reactions — redness, light bruising. The most common report.
  • 02Subjective energy in 2–4 wk — the most-reported early effect.
  • 03Glucose response shifts — improved insulin sensitivity is the targeted endpoint.
  • 04Effects build over a cycle — metabolic adaptations are gradual.
!

Not for

  • 01Pregnancy or breastfeeding. Insufficient safety data.
  • 02Active malignancy. Cellular metabolic stimulation requires oncologic oversight.
  • 03Type 1 diabetes without monitoring. Insulin sensitization changes require glucose monitoring.
  • 04Use without oversight. Always under a licensed physician's supervision.

Compounded MOTS-c is not an FDA-approved drug product. It is dispensed by a licensed 503A compounding pharmacy under a prescription written by a U.S.-licensed physician for individual investigational and off-label use under provider supervision. Statements on this page have not been evaluated by the FDA. Individual results vary.

09 Questions

Frequently asked.

What is MOTS-c?+

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrion (within the 12S rRNA gene). It was first reported in 2015 (Lee et al) and founded a new class — mitochondrially-derived peptides.

What does it do?+

It activates AMPK, sensitizes cells to insulin, and improves metabolic flexibility. In animal models it increases exercise capacity and improves features of metabolic syndrome.

How is it different from NAD+?+

NAD+ is a cofactor — substrate for the enzymes that already exist. MOTS-c is a signal — it changes which enzymes are active. They're complementary, often stacked.

Is the evidence strong?+

It's exploratory. The mechanism is well-characterized; human outcome data is still emerging. Honest answer: this is a newer-class peptide and the literature is younger than for BPC-157 or Sermorelin.

Can I stack it?+

Yes — common pairings include NAD+ (mitochondrial cofactor), Sermorelin (longevity stack), and Glutathione (redox foundation). Your physician designs the stack.

Side effects?+

Mild injection-site reactions are the most reported. No serious adverse effects established in the published literature to date. Glucose monitoring is appropriate for diabetic members.

Begin Ten minutes of intake

Begin your MOTS-c protocol.

Free assessment. A board-certified U.S. physician on the prescription. Bloodwork only if your protocol calls for it. Compounded fresh and cold-chain shipped overnight.

Start your intake Free · No card required · Rx required to ship

Other compounds in the roster.

All 8 therapies →
NAD+

Cellular energy coenzyme. Sirtuins, DNA repair, mitochondrial output. The longevity substrate.

From $200/mo Sermorelin

GHRH analog. Sleep depth, lean mass, recovery — pulses your own GH at night.

From $195/mo Glutathione

Master antioxidant. Skin clarity, immune resilience, and the redox baseline for everything else.

Pricing soon

Deeper guides on MOTS-c.

All guides →